Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure
Author Information
Author(s): Katsumata Kenji, Sumi Tetsuo, Wada Tatehiko, Mori Yasuharu, Hisada Masayuki, Kawakita Hideaki, Enomoto Masanori, Suzuki Shoji, Matsuda Daisuke, Tsuchida Akihiko, Aoki Tatsuya
Primary Institution: Tokyo Medical University
Hypothesis
What is the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin in a hemodialysis patient with cecal cancer?
Conclusion
More pharmacokinetic data is needed to understand the accumulation and dialysability of oxaliplatin in patients with renal failure.
Supporting Evidence
- The patient had cecal cancer and was on hemodialysis due to diabetic nephropathy.
- Oxaliplatin was administered at a reduced dose due to the patient's renal condition.
- Platinum levels decreased significantly during hemodialysis, indicating its dialysability.
Takeaway
This study looked at how a cancer drug called oxaliplatin works in a patient who needs dialysis. It found that the drug's levels in the blood drop during dialysis.
Methodology
The patient was treated with oxaliplatin and 5-FU, with blood samples collected to measure platinum clearance during hemodialysis.
Limitations
The study is based on a single patient, making it difficult to generalize the findings.
Participant Demographics
A 65-year-old man with a history of diabetes and chronic renal failure.
Want to read the original?
Access the complete publication on the publisher's website